Loading clinical trials...
Loading clinical trials...
A Phase I-II Study to Assess Venetoclax + Azacitidine and Donor Lymphocyte Infusion in Patients With MDS or AML in Relapse After Allohematopoietic Stem Cell Transplantation
Conditions
Interventions
venetoclax + azacitidine +/- donor lymphocyte infusion
Locations
11
France
CHU d'Angers
Angers, France
CHU de Grenoble
Grenoble, France
Hôpital Dupuytren
Limoges, France
Hôpital Saint-Eloi
Montpellier, France
CHU Hôtel Dieu
Nantes, France
Hôpital l'Archet I
Nice, France
Start Date
November 23, 2022
Primary Completion Date
November 15, 2026
Completion Date
September 1, 2027
Last Updated
March 12, 2026
NCT03050268
NCT06973668
NCT06656494
NCT05735717
NCT06465953
NCT07500441
Lead Sponsor
Groupe Francophone des Myelodysplasies
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions